With a potential FDA approval looming, G1 Therapeutics taps ex-GSK US president Jack Bailey as new CEO

There’s never a perfect time to step down from a leadership position, G1 Therapeutics CEO Mark Velleca said. But to him, this felt like the right one.

On January 1 — a month before the FDA rules on what could be the biotech’s first approved drug  — Velleca will pass the torch to GSK vet John “Jack” Bailey, who joined G1’s board in March. Bailey stepped down at GSK’s US president last year, where he gained considerable experience on the sales side.